THE DEAL, AT A GLANCE
2/4 explanations supportedIPremom
01What it doesiPremom provides MaiRa, a blood test that predicts pregnancy-complication risks early in pregnancy.Source-grounded · automated review · Explore ↗
Checked 2026-09-06 · Review due 2026-09-13
Read supporting source ↗iPremom currently makes MaiRa available…
02Who is involvedEvidence still neededOpen review status ↗
Supported. Document 0 says the €15 million seed funding was led by Amadeus Capital Partners, with participation from Asabys Partners and APEX Ventures. No unsupported previous-round investor claim is made.
03What happenedEvidence still neededOpen review status ↗
Supported as to round, currency, amount, and financing purpose. Document 0 states iPremom raised €15 million in seed funding to advance its molecular diagnostics platform, with proceeds planned for clinical validation, commercialization/commercial rollout, additional validation studies, and regulato
04Why it mattersThe funding supports validation, rollout and regulatory work for earlier pregnancy-risk detection.Interpretation · Explore ↗
Click a part to explore its evidence. Symbols are conceptual, not financial charts.Original record source ↗
IPremom · Financing Record
Explore source-linked visual explanations for IPremom. Unsupported claims are withheld while source review continues.
Record 11616 · Recorded date: 2026-09-04
Explore company records →